FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Efficacy of Invariant Natural Killer T Cell Infusion Plus Transarterial Embolization vs Transarterial Embolization Alone for Hepatocellular Carcinoma Patients: A Phase 2 Randomized Clinical Trial. PMID 37637501 · J Hepatocell Carcinoma · 2023 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Ataxia-telangiectasia clinical trial landscape and the obstacles to overcome. PMID 37622329 · Expert Opin Investig Drugs · 2023 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Protective effect of propofol compared with sevoflurane on liver function after hepatectomy with Pringle maneuver: A randomized clinical trial. PMID 37616308 · PLoS One · 2023 Eligibility requires a drug-containing anti-cancer intervention in a Phase III/IIIb or Phase II/III randomized trial with a time-to-event primary efficacy endpoint (e.g., OS, PFS). This study compares anesthetic agents (propofol vs. sevoflurane) for hepatoprotection during liver surgery, with liver function tests as endpoints. It is a randomized oncology surgery trial but lacks the required drug intervention, phase, and endpoint type. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A Multicenter Randomized Phase II Trial Investigating the Effect of Polyglycolic Acid Sheet on the Prevention of Pancreatic Fistula After Gastrectomy with Prophylactic Lymph Node Dissection. PMID 37614978 · Clin Exp Gastroenterol · 2023 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assay. PMID 37601688 · Front Oncol · 2023 The record is a secondary analysis from the randomized trial IMvigor010, not the primary result report. The trial phase (Phase III/IIIb or Phase II/III) is not explicitly confirmed in the metadata or abstract, failing a key eligibility criterion. Therefore, it is excluded despite meeting other criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| JK5G postbiotics attenuate immune-related adverse events in NSCLC patients by regulating gut microbiota: a randomized controlled trial in China. PMID 37601658 · Front Oncol · 2023 The record describes a randomized, double-blind, placebo-controlled trial in oncology (NSCLC) with a drug-containing intervention. However, the primary efficacy endpoint is objective response rate (ORR), and the secondary endpoints are quality of life, adverse effects, and biomarker/microbiome analyses. No time-to-event efficacy endpoint (e.g., overall survival, progression-free survival, disease-free survival) is reported or mentioned. Therefore, it does not meet the core criterion of having a primary or key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Bleeding risk with concomitant administration of VEGF-TKIs and anticoagulant agents. PMID 37598021 · Semin Oncol · 2023 This is a subgroup analysis of a randomized trial focusing on bleeding risk (safety) with a VEGF-TKI, not on a primary or key secondary time-to-event efficacy endpoint like OS or PFS. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Development and validation of prediction models for the prognosis of colon cancer with lung metastases: a population-based cohort study. PMID 37583430 · Front Endocrinol (Lausanne) · 2023 The record is a population-based cohort study developing and validating prognostic models for colon cancer with lung metastases. While it is randomized (for model development/validation) and analyzes survival (OS/CSS), it is not a randomized clinical trial testing a drug intervention. It is a prognostic modeling study using SEER data, not a Phase III/IIIb or Phase II/III trial of a drug-containing intervention. The 'Randomized Controlled Trial' publication type appears to be a misclassification. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Acupoint Thread Embedding Combined With Wenshen Bugu Decoction for the Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptom Among Postmenopausal Breast Cancer Patients: Study Protocol of a Randomized Controlled Trial. PMID 37565358 · Integr Cancer Ther · 2023 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Evaluate the Effectiveness of a Group Psychoeducational Intervention in Reducing the Level of Cancer-Related Fatigue in Women Receiving Chemotherapy for Breast Cancer: A Randomized Controlled Trial. PMID 37564460 · Adv Biomed Res · 2023 The record describes a randomized controlled trial in breast cancer patients evaluating a psychoeducational intervention for fatigue, but it lacks a drug-containing intervention and its primary efficacy endpoint is not a time-to-event outcome (e.g., OS, PFS). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant intermediate-course versus long-course chemoradiotherapy in T3-4/N0+ rectal cancer: Istanbul R-02 phase II randomized study. PMID 37547762 · Oncol Res · 2023 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Low Dose Olanzapine in the Prevention and Treatment of Carboplatin Induced Nausea and Vomiting: A Prospective Clinical Randomized Controlled Trial. PMID 37539930 · Curr Pharm Des · 2023 The study is a randomized trial in oncology patients with a drug intervention, but its primary endpoint is the rate of chemotherapy-induced nausea and vomiting control at specific time phases, not a standard time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The time-to-first-vomiting analysis using Kaplan-Meier is a symptom-related secondary analysis, not the primary/key efficacy endpoint for an oncology trial. Phase information is also unclear. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparison of two different doses of hyperbaric bupivacaine for intracavitary radiotherapy in patients with carcinoma cervix - A randomized control trial. PMID 37530238 · Indian J Cancer · 2023 The study is a randomized trial in oncology patients with a drug intervention (bupivacaine), but it evaluates anesthesia/surgical conditions (e.g., time to block regression, time to walking, satisfaction scores) as its primary outcome. It does not report a time-to-event efficacy endpoint (such as OS, PFS, DFS, etc.) or survival analysis (Kaplan-Meier, HR). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Invitation methods for Indigenous New Zealand Māori in lung cancer screening: Protocol for a pragmatic cluster randomized controlled trial. PMID 37527237 · PLoS One · 2023 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Will artificial intelligence be, one day, powerful enough to obviate the need of randomized clinical trials? PMID 37527054 · Hell J Nucl Med · 2023 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Aggressive intraoperative warming and postoperative pulmonary complications in elderly patients recovering from esophageal cancer surgery: sub-analysis of a randomized trial. PMID 37521353 · Front Med (Lausanne) · 2023 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| To compare neoadjuvant concurrent chemo-radiotherapy followed by surgery and neoadjuvant chemotherapy followed by surgery in carcinoma esophagus patients: A single institutional study in the Indian population. PMID 37470593 · J Cancer Res Ther · 2023 The record meets most criteria: oncology, human, randomized, drug intervention, time-to-event endpoint, and original result. However, the trial phase is not explicitly stated in the title, abstract, or metadata as Phase III/IIIb or Phase II/III. Eligibility is set to null because the phase criterion cannot be confirmed. Confidence is low due to this critical missing information. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Effects of physical exercise on rehabilitation of cancer patients undergoing radiotherapy. PMID 37470579 · J Cancer Res Ther · 2023 The study is a randomized controlled trial on exercise and quality of life in cancer patients, but it lacks a drug-containing intervention and does not report time-to-event endpoints like OS or PFS. It is not a Phase III trial, and the primary endpoints are cardiopulmonary fitness and quality of life, not time-to-event efficacy. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial. PMID 37455588 · Pediatr Dermatol · 2023 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Epidemiology and nomogram of pediatric and young adulthood osteosarcoma patients with synchronous lung metastasis: A SEER analysis. PMID 37437020 · PLoS One · 2023 This is a retrospective epidemiological study and nomogram construction using SEER registry data. It is not a randomized controlled trial, despite the 'Randomized Controlled Trial' publication type tag. There is no drug-containing intervention; the study analyzes patient characteristics and survival outcomes based on existing data. Therefore, it does not meet the core criteria for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Androgen deprivation therapy plus abiraterone or docetaxel as neoadjuvant therapy for very-high-risk prostate cancer: a pooled analysis of two phase II trials. PMID 37435500 · Front Pharmacol · 2023 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Evaluating the Effectiveness of Intravesical Instillation of BCG by Modified Maintenance Method in Patients With High-Risk Ta and T1 Bladder Cancer: A Randomized Clinical Trial. PMID 37435018 · Clin Med Insights Oncol · 2023 The study is a randomized trial of a drug (BCG) in human bladder cancer, but its primary efficacy endpoints are categorical recurrence and progression rates, not a time-to-event endpoint such as OS, PFS, DFS, or a Kaplan-Meier/HR analysis. Additionally, the clinical phase is not explicitly stated in the abstract. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Hypofractionated radiotherapy with immunochemotherapy for extensive-stage small-cell lung cancer. PMID 37350968 · Front Immunol · 2023 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A randomized, controlled trial to investigate cognitive behavioral therapy in prevention and treatment of acute oral mucositis in patients with locoregional advanced nasopharyngeal carcinoma undergoing chemoradiotherapy. PMID 37350940 · Front Oncol · 2023 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Establishment of a Bayesian network model to predict the survival of malignant peritoneal mesothelioma patients after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. PMID 37348853 · Int J Hyperthermia · 2023 The study is a retrospective analysis and model development study for predicting survival after CRS+HIPEC, not a prospective Phase III/IIIb or Phase II/III randomized controlled trial with a drug-containing intervention versus control. Although it involves oncology, human subjects, randomization (for splitting data), a time-to-event endpoint, and a drug intervention (chemotherapy), it fails the definitive phase and original trial report criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Genome-Wide Methylation Profiling in 229 Patients With Crohn's Disease Requiring Intestinal Resection: Epigenetic Analysis of the Trial of Prevention of Post-operative Crohn's Disease (TOPPIC). PMID 37331566 · Cell Mol Gastroenterol Hepatol · 2023 The record describes an epigenetic/biomarker analysis within a randomized trial of 6-mercaptopurine for Crohn's disease, not a human malignant neoplasm. The primary outcome is differential methylation associated with clinical recurrence, not a standard time-to-event oncology efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Management of Oligometastatic Disease in Esophagogastric Cancer: What Is the Evidence? PMID 37331340 · Oncol Res Treat · 2023 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Recipient vessels for free flaps in advanced facial oncologic defects. PMID 37329667 · Braz J Otorhinolaryngol · 2023 Study is a randomized trial on surgical technique for oncologic reconstruction, not a Phase II/III or Phase III drug trial. It lacks a drug intervention and a primary/key secondary time-to-event efficacy endpoint, making it ineligible for inclusion in an oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparing the quality of analgesia with ultrasound-guided pectoral nerve block and serratus anterior plane block II in patients undergoing modified radical mastectomy: a randomised clinical trial. PMID 37306272 · Anaesthesiol Intensive Ther · 2023 This is a randomized trial in oncology (breast cancer surgery) but is not a Phase III/IIIb or Phase II/III trial, does not have a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR), and does not evaluate a drug-containing intervention for anti-cancer efficacy. It is a comparison of analgesic techniques (nerve blocks). |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Clinical efficacy of pseudomonas aeruginosa injection combined with endostar in the treatment of malignant pleural effusion: a randomized trial. PMID 37303619 · Am J Transl Res · 2023 Cannot confirm the trial phase from the provided metadata or abstract. The study is described as a 'randomized trial' with a primary efficacy endpoint and drug interventions, but the phase (II/III or III) is not explicitly stated, and the deterministic review flagged phase evidence as unclear. Therefore, eligibility cannot be definitively established. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Guaranteed Income and Financial Treatment Trial (GIFT Trial or GIFTT): a 12-month, randomized controlled trial to compare the effectiveness of monthly unconditional cash transfers to treatment as usual in reducing financial toxicity in people with cancer who have low incomes. PMID 37275728 · Front Psychol · 2023 The record describes a protocol for a randomized controlled trial evaluating an unconditional cash transfer intervention for financial toxicity in cancer patients. It is not a report of a completed trial with results. The intervention is non-pharmacologic, and the primary endpoints are not time-to-event outcomes. It also lacks a drug-containing intervention and a phase designation. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Long-Term Safety and Efficacy of Eltrombopag for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia: Results of the ASPIRE Extension Study. PMID 37231838 · Acta Haematol · 2023 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| The effects of omega 3 fatty acids on the serum concentrations of pro inflammatory cytokines anddepression status in patients with bipolar disorder: A randomized double-blind controlled clinical trial. PMID 37213459 · J Res Med Sci · 2023 The study is not in oncology; it examines omega-3 fatty acids in bipolar disorder with depression and inflammatory biomarkers as endpoints, not a time-to-event efficacy endpoint in human malignant neoplasms. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Randomized phase II study of daily versus alternate-day administrations of S-1 for the elderly patients with completely resected pathological stage IA (tumor diameter > 2 cm)-IIIA of non-small cell lung cancer: Setouchi Lung Cancer Group Study 1201. PMID 37205678 · PLoS One · 2023 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Impact of valganciclovir therapy on severe IRIS-Kaposi Sarcoma mortality: An open-label, parallel, randomized controlled trial. PMID 37195970 · PLoS One · 2023 The report is a randomized trial of valganciclovir in Kaposi Sarcoma, but it does not report a time-to-event efficacy endpoint (OS, PFS, DFS, etc.) with Kaplan-Meier or HR. The primary outcome is mortality (a binary event) and incidence of severe-IRIS-KS, which are not time-to-event. The trial phase is not explicitly stated (e.g., Phase III). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Prospective study of computer-aided detection of colorectal adenomas in hospitalized patients. PMID 37191195 · Scand J Gastroenterol · 2023 The study is a randomized controlled trial on computer-aided detection (CADe) for colorectal adenomas, which is oncology-related and human. However, it does not involve a drug-containing intervention (CADe is a device/software) and the primary endpoint is adenoma detection rate (ADR), which is not a time-to-event efficacy endpoint (like OS, PFS, DFS, etc.). The phase is not explicitly stated as Phase III/IIIb or Phase II/III, and it is not a definitive trial for a drug intervention. Therefore, it does not meet the core eligibility criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| RWD-derived response in multiple myeloma. PMID 37167221 · PLoS One · 2023 The record describes a methodological pilot study evaluating a derived response algorithm using data from the BELLINI trial and a real-world cohort. It is not a report of original trial results (primary, secondary, or subgroup) of a randomized Phase III drug intervention trial. The publication type indicates 'Clinical Trial, Phase III', but the content is a secondary analysis of response assessment methodology, not the trial's efficacy results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy of two different dosages of prednisone for treatment of subacute thyroiditis: a single-centre, prospective, randomized, open-label, non-inferiority trial. PMID 37155300 · Endokrynol Pol · 2023 The study is a randomized trial of prednisone (a drug) with results, but it is for subacute thyroiditis, a non-malignant condition, and the primary outcome is treatment duration (a continuous endpoint), not a time-to-event efficacy endpoint like OS, PFS, etc. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Genetic characteristics and clinical-specific survival prediction in elderly patients with gallbladder cancer: a genetic and population-based study. PMID 37152947 · Front Endocrinol (Lausanne) · 2023 The study is a retrospective, population-based bioinformatics and prognostic modeling analysis of elderly gallbladder cancer patients. It is not a randomized controlled trial of a drug intervention and lacks Phase III/IIIb or Phase II/III trial evidence. The 'Randomized Controlled Trial' publication type appears to be a database error referring to the random split of data into training/validation cohorts. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy of eye movement desensitization and reprocessing therapy for fear of cancer recurrence among cancer survivors: a randomized single-case experimental design. PMID 37144665 · Eur J Psychotraumatol · 2023 Study evaluates psychological intervention (EMDR) for fear of cancer recurrence, not a drug-based cancer treatment, and uses psychological outcome measures, not time-to-event endpoints like OS or PFS. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The catalytic inhibitor epacadostat can affect the non-enzymatic function of IDO1. PMID 37122718 · Front Immunol · 2023 This record is a preclinical/mechanistic journal article that discusses a Phase III trial but does not present the trial's original results or report any time-to-event efficacy data. It is therefore not an original result report of a clinical trial. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial. PMID 37114054 · Front Immunol · 2023 The study is a non-randomized trial, failing the randomized trial requirement. The required phase (III/IIIb or II/III) is not explicitly established in the provided metadata, and the non-randomized design further excludes it from eligibility. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Prehabilitation to improve outcomes afteR Autologous sTem cEll transplantation (PIRATE): A pilot randomised controlled trial protocol. PMID 37104482 · PLoS One · 2023 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Construction and validation of a nomogram for HBV-related hepatocellular carcinoma: A large, multicenter study. PMID 37100384 · Ann Hepatol · 2023 The study is a prognostic nomogram development and validation study in HBV-related hepatocellular carcinoma. It is not a Phase III or definitive randomized trial of a drug intervention. The 'randomized' label in the publication type refers only to the random division of patients into training and validation cohorts for model development, not to a randomized trial of a therapeutic intervention. The analysis is retrospective and does not involve a drug-containing intervention arm compared to another. It is excluded because it lacks a drug intervention and is not a Phase III/IIIb or Phase II/III randomized trial of therapy. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Stereotactic focal radiotherapy as an alternative treatment for low-risk prostate cancer: Results of a single-arm monocenter Phase-II trial. PMID 37091187 · Front Oncol · 2023 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Sijunzi decoction granules in the prevention and treatment of recurrence of colorectal adenoma: Study protocol for a multicenter, randomized, double-blind, placebo-controlled trial. PMID 37089947 · Front Pharmacol · 2023 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| The Construction and Validation of a new Predictive Model for Overall Survival of Clear Cell Renal Cell Carcinoma Patients with Bone Metastasis Based on Machine Learning Algorithm. PMID 37078130 · Technol Cancer Res Treat · 2023 The study is a retrospective analysis of a public database (SEER) and an institutional cohort, not a randomized controlled trial of a drug intervention. It is a predictive modeling study using machine learning, not a report of a Phase III/IIIb or Phase II/III randomized trial of a drug with a time-to-event efficacy endpoint. Publication types include 'Randomized Controlled Trial', but the text and methods clearly describe a retrospective, non-randomized study, making the publication type tag inaccurate for this record. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparison of thoracoabdominal versus abdominal-transhiatal surgical approaches in Siewert type II adenocarcinoma at the esophagogastric junction: Protocol for a prospective multicenter randomized controlled trial. PMID 37064105 · Front Oncol · 2023 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Association between intraoperative dexmedetomidine and all-cause mortality and recurrence after laparoscopic resection of colorectal cancer: Follow-up analysis of a previous randomized controlled trial. PMID 37064099 · Front Oncol · 2023 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Crafting a prognostic nomogram for the overall survival rate of cutaneous verrucous carcinoma using the surveillance, epidemiology, and end results database. PMID 37051207 · Front Endocrinol (Lausanne) · 2023 The study is a retrospective prognostic nomogram analysis using a public database (SEER) with randomization for model training/validation, not a randomized trial of a drug intervention. It is not a Phase III/IIIb or Phase II/III randomized controlled trial of a therapeutic drug. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |